COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,003 Articles (22,627 medRxiv, 8,376 bioRxiv)

Most recent first Previous |  Page 826: Articles 8251-8260  | Next

SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine
Bruel, T., Pinaud, L., Tondeur, L., Planas, D., Staropoli, I., Porrot, F., Guivel-Benhassine, F., Attia, M., Pelleau, S., Woundenberg, T., Duru, C., Davy Koffi, A., Castelain, S., Fernandes-Pellerin, S., Jolly, N., Perrin de Facci, L., Roux, E., Ungeheuer, M.-N., Van Der Werf, S., White, M., Schwartz, O., Fontanet, A.
10.1101/2022.03.30.22273175 — Posted: 2022-03-30
Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines during the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
Kiss, Z., Wittmann, I., Polivka, L., Surjan, G., Surjan, O., Barcza, Z., Molnar, G. A., Nagy, D., Muller, V., Bogos, K., Nagy, P., Kenessey, I., Weber, A., Palosi, M., Szlavik, J., Schaff, Z., Szekanecz, Z., Muller, C., Kasler, M., Voko, Z.
10.1101/2022.03.27.22273000 — Posted: 2022-03-30
Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City
Bowen, A., Zucker, J. E., Shen, Y., Huang, S., Yan, Q., Annavajhala, M. K., Uhlemann, A.-C., Kuhn, L., Sobieszczyk, M. E., Castor, D.
10.1101/2022.03.29.22273044 — Posted: 2022-03-30
Prior vaccination enables a more robust immune response to Omicron infection
Lee, H. K., Knabl, L., Walter, M., Dai, Y., Knabl, L., Fussl, M., Caf, Y., Jeller, C., Knabl, P., Obermoser, M., Baurecht, C., Kaiser, N., Zabernigg, A., Wurdinger, G. M., Furth, P. A., Hennighausen, L.
10.1101/2022.03.24.22272837 — Posted: 2022-03-30
Key topics in pandemic health risk communication: A qualitative study of expert opinions and knowledge
Berg, S. H., Shortt, M. T., Roislien, J., Lungu, D. A., Thune, H., Wiig, S.
10.1101/2022.03.28.22273033 — Posted: 2022-03-30
Genetic surveillance of SARS-CoV-2 Mpro reveals high sequence and structural conservation prior to the introduction of protease inhibitor Paxlovid
Lee, J. T., Yang, Q., Gribenko, A., Perrin, B. S., Zhu, Y., Cardin, R., Liberator, P. A., Anderson, A. S., Hao, L.
10.1101/2022.03.29.486331 — Posted: 2022-03-30
Effect of COVID-19 vaccination on menstrual periods in a prospectively recruited cohort
Woon, E. V., Male, V.
10.1101/2022.03.30.22273165 — Posted: 2022-03-30
Psychosocial factors affecting COVID-19 vaccine uptake in the UK: a prospective cohort study (CoVAccS - wave 3)
Smith, L. E., Sim, J., Cutts, M., Dasch, H., Amlot, R., Sevdalis, N., Rubin, G. J., Sherman, S. M.
10.1101/2022.03.25.22272954 — Posted: 2022-03-30
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July - November 2021.
Starrfelt, J., Danielsen, A. S., Buanes, E. A., Juvet, L. K., Lyngstad, T. M., Roe, G. O. I., Veneti, L., Watle, S. V., Meijerink, H.
10.1101/2022.03.29.22273086 — Posted: 2022-03-30
Severe outcomes in unvaccinated COVID-19 cases <18 years during different variant waves in Norway
Whittaker, R., Greve-Isdahl, M., Boas, H., Suren, P., Buanes, E., Veneti, L.
10.1101/2022.03.29.22273093 — Posted: 2022-03-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).